Pharma & Healthcare
Global Benign Prostatic Hyperplasia (BPH) Drugs Market Research Report 2024
- Feb 19, 24
- ID: 52030
- Pages: 89
- Figures: 199
- Views: 12
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
The global Benign Prostatic Hyperplasia (BPH) Drugs market was valued at US$ 3329.5 million in 2023 and is anticipated to reach US$ 4195.1 million by 2030, witnessing a CAGR of 3.3% during the forecast period 2024-2030.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia (BPH) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia (BPH) Drugs.
Report Scope
The Benign Prostatic Hyperplasia (BPH) Drugs market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Benign Prostatic Hyperplasia (BPH) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
Segment by Type
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
Segment by Application
Hospitals
Drugstores
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Benign Prostatic Hyperplasia (BPH) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Benign Prostatic Hyperplasia (BPH) Drugs market was valued at US$ 3329.5 million in 2023 and is anticipated to reach US$ 4195.1 million by 2030, witnessing a CAGR of 3.3% during the forecast period 2024-2030.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia (BPH) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia (BPH) Drugs.
Report Scope
The Benign Prostatic Hyperplasia (BPH) Drugs market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Benign Prostatic Hyperplasia (BPH) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
Segment by Type
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
Segment by Application
Hospitals
Drugstores
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Benign Prostatic Hyperplasia (BPH) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Benign Prostatic Hyperplasia (BPH) Drugs Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Drugs
1.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Alpha-Blocker
1.2.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Estimates and Forecasts
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2019-2030
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2019-2030
1.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Benign Prostatic Hyperplasia (BPH) Drugs Market Competition by Manufacturers
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Product Type & Application
2.7 Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation and Trends
2.7.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue
2.7.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario by Region
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2019-2030
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2019-2024
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2025-2030
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2019-2030
3.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2019-2024
3.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2025-2030
3.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.4.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)
3.4.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.5.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)
3.5.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.7.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)
3.7.3 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2030)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2025-2030)
4.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2030)
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2030)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2024)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2025-2030)
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2030)
5.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024)
5.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2025-2030)
5.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2030)
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2030)
5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2024)
5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2025-2030)
5.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Astellas Pharma
6.3.1 Astellas Pharma Corporation Information
6.3.2 Astellas Pharma Description and Business Overview
6.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.3.5 Astellas Pharma Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Abbott
6.6.1 Abbott Corporation Information
6.6.2 Abbott Description and Business Overview
6.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.6.5 Abbott Recent Developments/Updates
6.7 Allergan
6.6.1 Allergan Corporation Information
6.6.2 Allergan Description and Business Overview
6.6.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.7.5 Allergan Recent Developments/Updates
6.8 TEVA
6.8.1 TEVA Corporation Information
6.8.2 TEVA Description and Business Overview
6.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.8.5 TEVA Recent Developments/Updates
6.9 Mylan
6.9.1 Mylan Corporation Information
6.9.2 Mylan Description and Business Overview
6.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.9.5 Mylan Recent Developments/Updates
6.10 Novartis
6.10.1 Novartis Corporation Information
6.10.2 Novartis Description and Business Overview
6.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.10.5 Novartis Recent Developments/Updates
6.11 Merck
6.11.1 Merck Corporation Information
6.11.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Description and Business Overview
6.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.11.5 Merck Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Chain Analysis
7.2 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process
7.4 Benign Prostatic Hyperplasia (BPH) Drugs Sales and Marketing
7.4.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels
7.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
7.5 Benign Prostatic Hyperplasia (BPH) Drugs Customers
8 Benign Prostatic Hyperplasia (BPH) Drugs Market Dynamics
8.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
8.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
8.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
8.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Drugs
1.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Alpha-Blocker
1.2.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Estimates and Forecasts
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2019-2030
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2019-2030
1.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Benign Prostatic Hyperplasia (BPH) Drugs Market Competition by Manufacturers
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Product Type & Application
2.7 Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation and Trends
2.7.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue
2.7.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario by Region
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2019-2030
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2019-2024
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2025-2030
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2019-2030
3.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2019-2024
3.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2025-2030
3.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.4.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)
3.4.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.5.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)
3.5.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.7.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)
3.7.3 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2030)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2025-2030)
4.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2030)
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2030)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2024)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2025-2030)
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2030)
5.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024)
5.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2025-2030)
5.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2030)
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2030)
5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2024)
5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2025-2030)
5.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Astellas Pharma
6.3.1 Astellas Pharma Corporation Information
6.3.2 Astellas Pharma Description and Business Overview
6.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.3.5 Astellas Pharma Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Abbott
6.6.1 Abbott Corporation Information
6.6.2 Abbott Description and Business Overview
6.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.6.5 Abbott Recent Developments/Updates
6.7 Allergan
6.6.1 Allergan Corporation Information
6.6.2 Allergan Description and Business Overview
6.6.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.7.5 Allergan Recent Developments/Updates
6.8 TEVA
6.8.1 TEVA Corporation Information
6.8.2 TEVA Description and Business Overview
6.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.8.5 TEVA Recent Developments/Updates
6.9 Mylan
6.9.1 Mylan Corporation Information
6.9.2 Mylan Description and Business Overview
6.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.9.5 Mylan Recent Developments/Updates
6.10 Novartis
6.10.1 Novartis Corporation Information
6.10.2 Novartis Description and Business Overview
6.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.10.5 Novartis Recent Developments/Updates
6.11 Merck
6.11.1 Merck Corporation Information
6.11.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Description and Business Overview
6.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.11.5 Merck Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Chain Analysis
7.2 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process
7.4 Benign Prostatic Hyperplasia (BPH) Drugs Sales and Marketing
7.4.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels
7.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
7.5 Benign Prostatic Hyperplasia (BPH) Drugs Customers
8 Benign Prostatic Hyperplasia (BPH) Drugs Market Dynamics
8.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
8.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
8.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
8.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) of Key Manufacturers (2019-2024)
Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Benign Prostatic Hyperplasia (BPH) Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2019-2024) & (M Units)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2019-2024)
Table 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2025-2030) & (M Units)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2025-2030)
Table 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)
Table 27. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2025-2030) & (M Units)
Table 28. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)
Table 32. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2025-2030) & (M Units)
Table 33. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2019-2024) & (M Units)
Table 37. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2025-2030) & (M Units)
Table 38. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)
Table 42. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2025-2030) & (M Units)
Table 43. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)
Table 47. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2025-2030) & (M Units)
Table 48. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2019-2024)
Table 51. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2025-2030)
Table 52. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2024)
Table 53. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2025-2030)
Table 54. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Type (2019-2024)
Table 59. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Type (2025-2030)
Table 60. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2019-2024)
Table 61. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2025-2030)
Table 62. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2024)
Table 63. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2025-2030)
Table 64. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Application (2019-2024)
Table 69. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Application (2025-2030)
Table 70. Eli Lilly Corporation Information
Table 71. Eli Lilly Description and Business Overview
Table 72. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 74. Eli Lilly Recent Developments/Updates
Table 75. GlaxoSmithKline Corporation Information
Table 76. GlaxoSmithKline Description and Business Overview
Table 77. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 79. GlaxoSmithKline Recent Developments/Updates
Table 80. Astellas Pharma Corporation Information
Table 81. Astellas Pharma Description and Business Overview
Table 82. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 84. Astellas Pharma Recent Developments/Updates
Table 85. Sanofi Corporation Information
Table 86. Sanofi Description and Business Overview
Table 87. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 89. Sanofi Recent Developments/Updates
Table 90. Pfizer Corporation Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 94. Pfizer Recent Developments/Updates
Table 95. Abbott Corporation Information
Table 96. Abbott Description and Business Overview
Table 97. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 99. Abbott Recent Developments/Updates
Table 100. Allergan Corporation Information
Table 101. Allergan Description and Business Overview
Table 102. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 104. Allergan Recent Developments/Updates
Table 105. TEVA Corporation Information
Table 106. TEVA Description and Business Overview
Table 107. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 109. TEVA Recent Developments/Updates
Table 110. Mylan Corporation Information
Table 111. Mylan Description and Business Overview
Table 112. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 114. Mylan Recent Developments/Updates
Table 115. Novartis Corporation Information
Table 116. Novartis Description and Business Overview
Table 117. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 119. Novartis Recent Developments/Updates
Table 120. Merck Corporation Information
Table 121. Merck Description and Business Overview
Table 122. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 124. Merck Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table 128. Benign Prostatic Hyperplasia (BPH) Drugs Customers List
Table 129. Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
Table 130. Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
Table 131. Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
Table 132. Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2023 & 2030
Figure 4. Alpha-Blocker Product Picture
Figure 5. Phosphodiesterase Type-5 Inhibitors Product Picture
Figure 6. Others Product Picture
Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2023 & 2030
Figure 9. Hospitals
Figure 10. Drugstores
Figure 11. Others
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2019-2030) & (US$ Million)
Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (2019-2030) & (M Units)
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price (US$/Unit) & (2019-2030)
Figure 16. Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered
Figure 17. Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers in 2023
Figure 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players: Market Share by Revenue in 2023
Figure 20. Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2019-2030)
Figure 23. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2019-2030)
Figure 24. U.S. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2019-2030)
Figure 27. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2019-2030)
Figure 28. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2019-2030)
Figure 35. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Indonesia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Thailand Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Malaysia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Philippines Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2019-2030)
Figure 46. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2019-2030)
Figure 47. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2019-2030)
Figure 51. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2019-2030)
Figure 52. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. UAE Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2019-2030)
Figure 56. Global Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2019-2030)
Figure 57. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Type (2019-2030)
Figure 58. Global Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2019-2030)
Figure 59. Global Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2019-2030)
Figure 60. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Application (2019-2030)
Figure 61. Benign Prostatic Hyperplasia (BPH) Drugs Value Chain
Figure 62. Benign Prostatic Hyperplasia (BPH) Drugs Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) of Key Manufacturers (2019-2024)
Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Benign Prostatic Hyperplasia (BPH) Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2019-2024) & (M Units)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2019-2024)
Table 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2025-2030) & (M Units)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2025-2030)
Table 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)
Table 27. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2025-2030) & (M Units)
Table 28. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)
Table 32. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2025-2030) & (M Units)
Table 33. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2019-2024) & (M Units)
Table 37. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2025-2030) & (M Units)
Table 38. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)
Table 42. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2025-2030) & (M Units)
Table 43. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)
Table 47. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2025-2030) & (M Units)
Table 48. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2019-2024)
Table 51. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2025-2030)
Table 52. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2024)
Table 53. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2025-2030)
Table 54. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Type (2019-2024)
Table 59. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Type (2025-2030)
Table 60. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2019-2024)
Table 61. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2025-2030)
Table 62. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2024)
Table 63. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2025-2030)
Table 64. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Application (2019-2024)
Table 69. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Application (2025-2030)
Table 70. Eli Lilly Corporation Information
Table 71. Eli Lilly Description and Business Overview
Table 72. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 74. Eli Lilly Recent Developments/Updates
Table 75. GlaxoSmithKline Corporation Information
Table 76. GlaxoSmithKline Description and Business Overview
Table 77. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 79. GlaxoSmithKline Recent Developments/Updates
Table 80. Astellas Pharma Corporation Information
Table 81. Astellas Pharma Description and Business Overview
Table 82. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 84. Astellas Pharma Recent Developments/Updates
Table 85. Sanofi Corporation Information
Table 86. Sanofi Description and Business Overview
Table 87. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 89. Sanofi Recent Developments/Updates
Table 90. Pfizer Corporation Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 94. Pfizer Recent Developments/Updates
Table 95. Abbott Corporation Information
Table 96. Abbott Description and Business Overview
Table 97. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 99. Abbott Recent Developments/Updates
Table 100. Allergan Corporation Information
Table 101. Allergan Description and Business Overview
Table 102. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 104. Allergan Recent Developments/Updates
Table 105. TEVA Corporation Information
Table 106. TEVA Description and Business Overview
Table 107. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 109. TEVA Recent Developments/Updates
Table 110. Mylan Corporation Information
Table 111. Mylan Description and Business Overview
Table 112. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 114. Mylan Recent Developments/Updates
Table 115. Novartis Corporation Information
Table 116. Novartis Description and Business Overview
Table 117. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 119. Novartis Recent Developments/Updates
Table 120. Merck Corporation Information
Table 121. Merck Description and Business Overview
Table 122. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 124. Merck Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table 128. Benign Prostatic Hyperplasia (BPH) Drugs Customers List
Table 129. Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
Table 130. Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
Table 131. Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
Table 132. Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2023 & 2030
Figure 4. Alpha-Blocker Product Picture
Figure 5. Phosphodiesterase Type-5 Inhibitors Product Picture
Figure 6. Others Product Picture
Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2023 & 2030
Figure 9. Hospitals
Figure 10. Drugstores
Figure 11. Others
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2019-2030) & (US$ Million)
Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (2019-2030) & (M Units)
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price (US$/Unit) & (2019-2030)
Figure 16. Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered
Figure 17. Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers in 2023
Figure 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players: Market Share by Revenue in 2023
Figure 20. Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2019-2030)
Figure 23. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2019-2030)
Figure 24. U.S. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2019-2030)
Figure 27. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2019-2030)
Figure 28. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2019-2030)
Figure 35. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Indonesia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Thailand Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Malaysia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Philippines Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2019-2030)
Figure 46. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2019-2030)
Figure 47. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2019-2030)
Figure 51. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2019-2030)
Figure 52. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. UAE Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2019-2030)
Figure 56. Global Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2019-2030)
Figure 57. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Type (2019-2030)
Figure 58. Global Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2019-2030)
Figure 59. Global Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2019-2030)
Figure 60. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Application (2019-2030)
Figure 61. Benign Prostatic Hyperplasia (BPH) Drugs Value Chain
Figure 62. Benign Prostatic Hyperplasia (BPH) Drugs Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
DigitalBroadcast and Cinematography Cameras Lease - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Mobile and Web Event Analytics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Business Information - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232